Cell-based therapies have offered a new paradigm in the management of T2DM by creating an unlimited source of insulin-producing cells, repairing β cell function, modulating metabolism, and improving immune dysfunction [6]. This evidence concerns the gene INS and type 2 diabetes mellitus.